Abstract library

7 results for "Segelov".
#1310 Current Trials in Neuroendocrine Tumours: A Systematic Review
Introduction: Trials in neuroendocrine tumours (NETs) have increased markedly in number over the last 10 years. Researchers do not have ready access to a summary of open trials to identify research gaps.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: ...none of the above
Presenting Author: Dr David Chan
Authors: Chan D, Segelov E, Millican J, Singh S, ...
Keywords: trials, review
#1358 Identifying and Prioritising Gaps in Neuroendocrine Tumour Research - Results of the Delphi Consensus Project of the Commonwealth Neuroendocrine Tumour Research Collaboration (CommNETS)
Introduction: The newly formed CommNETS group used the robust Delphi methodology with broad stakeholder engagement to form a strategic research agenda.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: ...none of the above
Presenting Author: A/P Eva Segelov
#1366 CommNETS: Formation of an International Commonwealth Countries NET Partnership
Introduction: Neuroendocrine tumours (NETs) care is challenging in Canada, Australia and New Zealand due to small populations in large geographical space, limited drug funding, and lack of NET awareness. There is a need for collaboration to focus research and improve care and outcomes for NET patients in these nations with similar health systems.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: ...none of the above
Presenting Author: Dr. Simron Singh
Authors: Singh S, Lawrence B, Chan D, Pavlakis N, ...
Keywords: research, society
#1719 Escalated Dose Somatostatin Analogues for Anti-Proliferative Effect in Gastroenteropancreatic Neuroendocrine Tumours (GEPNETS): A Systematic Review
Introduction: Somatostatin analogues (SSAs) are the cornerstone of systemic therapy for well-differentiated GEPNETs. Dose escalation of SSAs is often trialled in clinical practice, but small studies have yielded mixed results.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr David Chan
#1920 Optimising Followup after Complete Surgical Resection of Gastrointestinal Neuroendocrine Tumours- A Delphi Process to Produce Expert Consensus in an Area Lacking Clinical Evidence
Introduction: Optimal follow-up for completely resected GI-NETS has not been well defined, with heterogeneity in awareness and application of existing guidelines.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: ...none of the above
Presenting Author: Lesley Moody
Authors: Moody L, Segelov E, Chan D, Carsley S, ...
Keywords: RAM, NET
#2713 The Economic Impact to Patients with Neuroendocrine Tumours
Introduction: The quality of life impact on patients with neuroendocrine tumours (NETs) and the economic burden on health systems are substantial. However, little is known about the economic burden to individual patients and families for medical out-of-pocket expenses and employment decisions.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Assoc Prof David Wyld
Authors: Wyld D, Elliott T, Wakelin K, Leyden S, ...
#2923 Interim Analysis of Prospective Evaluation of the Management of Sporadic Nonfunctioning Asymptomatic Pancreatic Neuroendocrine Neoplasms ≤ 2 cm (ASPEN Study)
Introduction: Guidelines recommend a watchful strategy for small, incidental, nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNEN).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr, PhD Stefano Partelli